ADC Therapeutics SA Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
ADC Therapeutics SA quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2023 to Q3 2024.
  • ADC Therapeutics SA Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$44M, a 5.9% increase year-over-year.
  • ADC Therapeutics SA Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$212M.
  • ADC Therapeutics SA annual Net Income (Loss) Attributable to Parent for 2023 was -$240M, a 52.8% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$212M -$44M +$2.76M +5.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$215M -$36.5M +$12.4M +25.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$227M -$46.6M +$12.8M +21.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 -$240M -$85M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 -$46.7M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$48.9M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$59.4M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.